3 stories mentioning ANIP
Every FINWIRES story that references ANIP, newest first.
Patrick D Walsh, Director, on May 11, 2026, sold 13,973 shares in Ani Pharmaceuticals (ANIP) for $1,127,120. Following the Form 4 filing with the SEC, Walsh has control over a total of 38,432 common shares of the company, with 38,432 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1023024/000172056826000005/xslF345X05/wk-form4_1778718127.xml
Healthcare stocks were steady pre-bell Friday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) down a slight 0.1%.Grifols (GRFS) stock was up more than 2% after the company posted a higher Q1 adjusted profit.ANI Pharmaceuticals (ANIP) shares were up more than 4% after the company reported higher Q1 adjusted earnings and net revenue, and raised its 2026 outlook.Artiva Biotherapeutics (ARTV) stock was up more than 3% after the company priced its $300 million underwritten offering of common shares and pre-funded warrants.
Health care stocks were leaning lower premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) declining by 0.4% and the iShares Biotechnology ETF (IBB) down 0.5%.Biogen (BIIB) has agreed to acquire TJ Biopharma's rights to the felzartamab antibody in the Greater China Region under a definitive agreement, the companies said. Biogen shares were up more than 1% pre-bell.AstraZeneca (AZN) said its pivotal phase 3 study of tozorakimab demonstrated a "significant" reduction in the annual rate of moderate-to-severe chronic obstructive pulmonary disease, or COPD, exacerbations in trial participants. Shares of AstraZeneca were down more than 1% premarket.ANI Pharmaceuticals (ANIP) stock was up more than 1% after the company said it has received US Food and Drug Administration approval and launched Pimozide Tablets in 1 mg and 2 mg doses, the generic version of Orap, with 180-day Competitive Generic Therapy exclusivity.